JPMorgan analyst Lisa Gill raised the firm’s price target on Privia Health (PRVA) to $33 from $32 and keeps an Overweight rating on the shares. The firm updated the company’s estimates post earnings.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA:
- BMO Capital Highlights Privia Health Group’s Strong Growth Potential and Differentiated Risk Management in Value-Based Care
- Privia Health initiated with an Outperform at BMO Capital
- Privia Health price target raised to $34 from $32 at Canaccord
- Privia Health price target raised to $23 from $22 at Barclays
- Privia Health’s Earnings Call Highlights Robust Growth